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Abstract: We designed a high-sensitivity magnetic resonance imaging contrast agent that could be used
to diagnose diseases. First, magnetic nanocrystals were synthesized by a thermal decomposition method
on an organic solvent to obtain a high magnetism and methoxy poly(ethylene glycol)-poly(lactic acid) as
an amphiphilic polymer using the ring-opening polymerization method to stably disperse the magnetic
nanocrystals in an aqueous phase. Subsequently, the magnetic nanoclusters simultaneously self-assembled
with methoxy poly(ethylene glycol)-poly(lactic acid) using the nano-emulsion method to form magnetic
nanoclusters. Because their shape was similar to a raspberry, they were named PEGylated magnetic
nano-assemblies. The PEGylated magnetic nano-assemblies were dispersed stably in the aqueous phase
with a uniform size of approximately 65–70 nm for an extended period (0 days: 68.8± 5.1 nm, 33 days:
69.2 ± 2.0 nm, and 44 days: 63.2± 5.6). They exhibited both enough of a magnetic resonance (MR)
contrast effect and biocompatibility. In an in vivo study, the PEGylated magnetic nano-assemblies
provided a high contrast effect for magnetic resonance images for a long time after one treatment,
thereby improving the diagnostic visibility of the disease site.
Keywords: Magnetic resonance image; PEGylated; Poly(ethylene glycol)-poly(lactic acid); contrast agent
1. Introduction
Magnetic resonance (MR) imaging is the best investigative tool to obtain tomographic images
with a high resolution and to offer excellent anatomical information in living organisms. Its detection
capability can be greatly enhanced using MR contrast agents that enable noninvasive monitoring
and disease identification [1–17]. Magnetic nanocrystals synthesized in an organic phase have
well-defined crystallized structures and a high magnetic sensitivity, and they have been reported
to be used as contrast agents [4,18,19]. Of course, since they are dispersed in the organic phase,
additional surface modification with a hydrophilic layer (e.g., polyethylene glycol (PEG)) is required to
improve their colloidal stability in the aqueous phase [7,9,10,12,20–22]. PEG has a high hydrophilicity,
a low cytotoxicity, as well as a high cell permeability; in particular, it contributes to diminishing
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nonspecific interactions with serum proteins by forming hydrogen bonds with water molecules,
leading to an increasing residence (circulation) time in the blood [12,15,23–39]. Two main surface
modification methods are used for PEG-based materials: (1) the exchange method, in which the
hydrophobic ligand on the magnetic nanocrystal (MNC) surface is exchanged with PEG at a high
temperature, and (2) the addition method, in which the surface of a hydrophobic MNC is wrapped
(or coated or covered) with the emulsion method using a PEG-based amphiphilic polymer as a
surfactant [23–25,27,31–38,40–42]. This addition method enables the fabrication of a multifunctional
nanocomposite by simultaneously loading drugs and fluorescent materials as well as MNCs. However,
obtaining uniformly sized nanoparticles, especially nanoclusters, is not easy. There is a limitation in
increasing the size of MNCs to enhance the saturation magnetization (Ms) because it also induces
the transition between the supermagnetic-ferrimagnetic transitions. Instead, it has been reported that
a method of maintaining the superparamagnetic behaviour with a high magnetization by forming
magnetic nanoclusters (or assemblies) is effective. Magnetic nanoparticles composed of multiple single
MNCs are particularly attractive due to their high magnetic susceptibility, low coercive force, and high
magnetic properties [4,43,44].
Herein, we have developed high-sensitivity MRI contrast agents that improve the diagnostic
visibility of the disease site. We synthesized mPEG-PLA as a surfactant and then wrapped
(encapsulated) hydrophobic 12-nm MNCs with mPEG-PLA using the nano-emulsion method.
The particles are formed by homogeneously aggregating MNCs that are dispersed stably in a water
phase and are named PEGylate magnetic nano-assemblies (PEGylated MNs).
2. Materials and Methods
2.1. Materials
Methoxy polyethylene glycol (mPEG) (5 kDa), stannous octoate (Sn(Oct)2), 3,6-dimethyl-1,4-
dioxane-2,5-dione (lactide; LA), chloroform, iron (III) acetylacteonate (Fe(acac)3), manganese (II)
acetylacetonate (Mn(acac)2), 1,2-hexadexanediol, lauric acid, laurylamine, and benzyl ether were
purchased from Sigma-Aldrich (St. Louis, MO, USA). All other chemicals and reagents were of
analytical grade. The cell proliferation kit I (MTT) was purchased from Roche (Basel, Switzerland).
2.2. Synthesis of Magnetic Nanocrystals (MNCs)
As previously described, we synthesized hydrophobic magnetic nanocrystals (MNCs and
MnFe2O4) in an organic solvent using the thermal decomposition method [4,7,9,10,12,18–22]; 2 mmol
of Fe(acac)3, 1 mmol of Mn(acac)2, 10 mmol of 1,2-hexadecanediol, 6 mmol of lauric acid, and 6 mmol
of laurylamine were dissolved in benzyl ether (20 mL) under an ambient nitrogen atmosphere.
This mixture was preheated to 200 ◦C for 2 h under uniform stirring and then refluxed at 300 ◦C for 1 h.
After completion of this reaction, the reactants were cooled down to room temperature and purified
with an excess of ethyl alcohol (99.9%) for the products. The MNCs of about 12 nm were obtained
using the seed-mediated growth method.
2.3. Synthesis of mPEG-PLA by Ring-Opening Polymerization
The methoxy poly(ethylene glycol)-poly(lactic acid) (mPEG-PLA) as amphiphilic polymers were
synthesized by the ring opening polymerization (ROP) method, which the polymerized lactide
monomers in the presence of mPEG and Sn(Oct)2 were the catalyst through the use of the bulk
method. Briefly, dried mPEG (2 g, 0.4 µmol), lactide (0.8 g, 5.55 µmol), and Sn(Oct)2 (100 µL) were
completely dissolved in 50 mL of toluene at 120 ◦C under a nitrogen atmosphere. After completely
melting for 2 h, the mixture was slowly heated to 180 ◦C for 4 h. After the reaction was terminated,
the heat source was removed from the reactant and the temperature was cooled down to room
temperature. The solvent of this reactant was rapidly eliminated using a rotary evaporator (50 HZ,
EYELA). For purification, this reactant was redissolved in toluene (2 mL) and precipitated in excess
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cold diethyl ether, and then, it was filtered using a vacuum filtration. This purification process was
repeated three times. The reactant was freeze-dried to obtain a purified product as a white powder
and stored under a vacuum before use. The synthesized mPEG-PLA was analyzed using FTIR and
1H-NMR spectroscopy with CDCl3. The critical micelle concentration (CMC) of mPEG-PLA was
measured by conductivity. The conductivity (µS cm−1) of the mPEG-PLA solutions with various
concentrations was measured using a conductivity meter. The mPEG-PLA concentration was plotted
against the conductivity. The CMC was identified as the point on a plot where the slope changes.
2.4. Preparation of PEGylated Magnetic Nano-Assemblies (PEGylated MNs)
The PEGylated MNs were prepared by a nano-emulsion method. The mPEG-PLA solution and
MNC-containing organic phase were prepared by dissolving mPEG-PLA (100 mg) and MNC (20 mg)
in deionized water (20 mL) and methylene chloride (4 mL), respectively.
Afterwards, the MNC-containing organic solvent was poured into the mPEG-PLA solution.
This solution was ultra-sonicated in an ice bath for 20 min at 450 rpm and stirred overnight at room
temperature to evaporate methylene chloride. The resulting suspension was centrifuged 3 times
for 30 min each at 18,000 rpm. After the supernatant was removed, the precipitated PEGylated
MNs was re-dispersed in 5 mL of DI water. After the preparation, the size distributions and
surface charges of the PEGylated MNVs were analyzed by a particle size and zeta-potential analyzer
(ELS-Z, Otsuka Electronics). Additionally, its colloidal stability was analyzed by measuring the size
variation, monitoring for 44 days. Their morphologies and magnetic properties were analyzed by
transmittance electron microscopy (TEM, TECNAI G2, FEI) and a vibrating-sample magnetometer
(VSM) at 298K, respectively. The weight ratio (%) of mPEG-PLA in the samples was measured using
thermos-gravimetric analysis. Finally, the relaxivity (R2) data were obtained by using magnetic
resonance (MR) imaging analysis.
2.5. Biocompatibility Tests
The biocompatibility of mPEG-PLA and PEGylated MNs against NIH3T6.7 cells was evaluated
by measuring the inhibition of cell proliferation using the MTT assay kit. The NIH3T6.7 cells were
maintained in Dulbecco’s modified eagle′s medium (DMEM) containing fetal bovine serum (FBS)
(10%) and antibiotics (1%) at 37 ◦C in a humidified atmosphere with 5% CO2. Seeded were 104 cells
per well into a 96-well plate, and they were incubated at 37 ◦C overnight to attach onto the wells. Then,
they were treated with various concentrations of mPEG-PLA and the PEGylated MN solution and
further incubated for 24 h. The MTT assay was performed depending on the procedure recommended
by the manual. The cell viability (%) was determined as the ratio of purple intensity in viable cells
treated with mPEG-PLA and PEGylated MNs to the intensity in nontreated (control) cells. The cell
viability was normalized to that of the control cells (which were considered to have 100% cell viability).
2.6. In Vivo (Mouse Xenograft Tumor) Model Procedure
We performed mouse xenograft in tumor models, in which NIH3T6.7 cells (107 cells in 50 µL of
saline per animal) were implanted in the proximal thigh region of BALB/c-nude mice (4–5 weeks
of age) [7,11,45]. Then, the MR imaging was performed using 5 mice 4 weeks after the tumor cell
transplantation. All animal experiments were conducted with the approval of the Association for
Assessment and Accreditation of Laboratory Animal Care (AAALAC) International.
2.7. MR Imaging Procedure
We performed the MR imaging experiment of a PEGylated MN solution with a 1.5 T clinical MRI
instrument with a micro47 surface coil (Intera; Philips Medical Systems, Best, the Netherlands).
The T2 weights of various concentrations of PEGylated MN solution were measured by the
Carr–Purcell–Meiboom–Gill (CPMG) sequence at room temperature with the following parameters:
TR = 10 s, 32 echoes with a 12-ms even echo space, number of acquisitions = 1, point resolution of
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156 × 156 mm, and section thickness of 0.6 mm. The relaxivity coefficient (mM−1 s−1) was equal to
the ratio of R2 (1/T2, S−1) to the PEGylated MN concentration. In addition, in vivo MR imaging
experiments were performed with a 3 T clinical MRI instrument with a micro-47 surface coil (Intera;
Philips Medical Systems, Best, the Netherlands). The T2 weights of a nude mouse injected with
PEGylated MNs were measured by the CPMG sequence at room temperature with the following
parameters: TR = 10 s, 32 echoes with a 12-ms even echo space, number of acquisitions = 1, point
resolution of 156 × 156 mm, and section thickness of 0.6 mm. For the T2-weighted MR imaging
of the nude mouse model, we adopted the following parameters: resolution of 234 × 234 mm,
section thickness of 2.0 mm, TE = 60 ms, TR = 4000 ms, and number of acquisitions = 1.
3. Results and Discussion
3.1. Synthesis and Characterization of mPEG-PLA
We synthesized mPEG-PLA as an amphiphilic copolymer that could effectively encapsulate
hydrophobic magnetic nanocrystals through ring-opening polymerization (Figure 1) [23–25,27,31–38,41].
mPEG(5K)-PLA(2K) was obtained by controlling the feed ratio (LA/EG), and its chemical structure
was confirmed using FTIR and an 1H-NMR spectrometer (Figure 2) [28,33,35–37,43]. The hydroxyl
groups at the end of mPEG acted as the initiators, and the lactide monomers for the attachment
and growth of the PLA blocks were located at the end of PEG. mPEG-PLA commonly showed an
absorption that was assigned to the C–O–C band of mPEG (1087–1184 cm−1), the –C=O stretching
of lactide (LA) (1750–1760 cm−1), and the –CH2– stretching of mPEG (2850–2950 cm−1). However,
compared with that of LA, the strong peak at 1150–1300 cm−1 indicated the C–C(=O)–O vibration
of LA disappeared (Figure 2a). As shown in Figure 2b, the peaks corresponding to the methylene
(–CH2–) and methoxy end (CH3O–) groups of mPEG were still confirmed at approximately 3.38 ppm
and 3.64 ppm, respectively, but the peak corresponding to the hydroxyl (–OH) group was no longer
observed at 4.79 ppm. Additionally, the methyne (CH) and methyl (–CH3) groups were observed in
PLA at 5.17 ppm and 1.60 ppm, respectively. These spectra indicated that mPEG-PLA was successfully
synthesized. We also measured the conductivity of mPEG-PLA to confirm its applicability as an
amphiphilic polymer. The conductivity increases almost linearly with the mPEG-PLA concentration;
after a certain concentration is reached, the conductivity increases linearly with the lower slope.
This concentration at which the slope of conductivity changes was identified as the critical micelle
concentration (CMC) (Figure 3) [39,46]. This result indicated that the surfactant adsorption at the
interface did not increase until the mPEG-PLA concentration reached 5.496 µM; however, the further
addition of mPEG-PLA resulted in the formation of micelles in the solution.
Nanomaterials 2019, x, x FOR PEER REVIEW  4 of 12 
 
Purcell–Meiboom–Gill (CPMG) sequence at room temperature with the following parameters: TR = 
10 s, 32 echoes with a 12-ms even echo space, number of acquisitions = 1, point resolution of 156 × 156 
mm, and section thickness of 0.6 mm. The relaxivity coefficient (mM−1 s−1) was equal to the ratio of R2 
(1/T2, S−1) to the PEGylated MN concentration. In addition, in vivo MR imaging experiments were 
performed with a 3 T clinical MRI instrument with a micro-47 surface coil (Intera; Philips Medical 
Systems, Best, the Netherlands). The T2 weights of a nude mouse injected with PEGylated MNs were 
measured by the CPMG sequence at room temperature with the following parameters: TR = 10 s, 32 
echoes with a 12-ms even echo space, number of acquisitions = 1, point resolution of 156 × 156 mm, 
and section thickness of 0.6 mm. For the T2-weighted MR imaging of the nude mouse model, we 
adopted the following parameters: resolution of 234 × 234 mm, section thickness of 2.0 mm, TE = 60 
ms, TR = 4000 ms, and number of acquisitions = 1. 
3. es lts a  isc ssi  
. .   i i  f -   
e synthesize  -  as a  a i ilic c l r t t c l  effecti l  e c s l t  
rophobic magnetic nanocrystals through ring-opening polymerization (Figure 1) [ 3–25,27 3 –
38,41]. mPEG(5K)-PLA(2K) was o tained by controlling the feed ratio (LA/EG), and its chemical 
structure was confirmed usi g FTIR and an 1H-NMR spectrometer (Figure 2) [28, 3,35–37,43]. The 
hydroxyl groups at the end of mPEG acted as the initiators, and the lactide monomers for the 
ttachment and growth of the PLA blocks were located at the end of PEG. mPEG-PLA commonly 
showed a  absorption that was assigned to the C–O–C band of mPEG (1087–1184 cm−1), h  –C=O 
stret hing of lactide (LA) (1750–1760 cm−1), and the –CH2– stretching of mPEG (2850–2950 cm−1). 
Howev r, compared with that of LA, the strong peak at 1150–1300 cm−1 indicated the C–C(=O)–O 
vibration of LA disappeared (Figure 2a). As shown in Figur  2b, the peaks corresponding to th  
methylene (–CH2–) and methoxy end (CH3O–) groups of mPEG were still confirmed at pproximately 
3.38 ppm and 3.64 ppm, respectiv ly, but the peak corresponding t  the hydroxyl (–OH) gr up was 
no longer observed at 4.79 ppm. Additionall , the methyne (CH) and methyl (–CH3) groups were 
observed in PLA at 5.17  and 1.60 ppm, r pectively. These spectra indicated th t mPEG-PLA 
was succ ssfully synthesized. We also measured the conductivity f mPEG-PLA to confirm its 
p licability as an amp iphilic polymer. The conductivity increases almost linearly with the mPEG-
PLA concentrati ; af er a certain concen ration is reached, the conductivity increases linearly with 
t e lower slope. This concen ration at which the slope of conductivity changes was identified as th  
ritical micelle concentration (CMC) (Figure 3) [39,46]. This result indic ted hat the surf ctant 
adsorption at the interface did not increase until the mPEG-PLA concentration reached 5.496 μM; 
however, the further addition of mPEG-PLA resulted in the formati n of micelles in the solution. 
 
Figure 1. A schematic illustration of PEGylated magnetic nano-assembly (PEGylated MN) synthesis 
using mPEG-PLA and magnetic nanocrystals (MNCS) as an effective MRI contrast agent. 
i r 1. sc tic ill str ti f l t a etic a - ss l ( l t ) s t sis
i - a a etic a ocrystals ( S) ff ti I tr t t.
Nanomaterials 2019, 9, 410 5 of 12
Nanomaterials 2019, x, x FOR PEER REVIEW  5 of 12 
 
 
Figure 2. (a) The FTIR spectra of mPEG (5K) (black), lactide (red), and mPEG-PLA (blue) and (b) the 
1H-NMR spectrum of mPEG-PLA (CDCl3: Solvent). 
 
Figure 3. The determination of the critical micelle concentration (CMC) of mPEG-PLA using 
conductivity. 
3.2. Formulation and Characterization of PEGylated MNs  
We fabricated PEGylated magnetic nanoparticles composed of hydrophobic magnetic 
nanocrystals (MNCs) encapsulated by mPEG-PLA using the nano-emulsion method [3,7–13,16,20–
22,39,45,47,48]. The morphologies of these particles confirmed by TEM showed that MNCs were 
clustered spherically (Figure 4a). Based on this TEM image, we denoted this nanoparticle as a 
PEGylated magnetic nanoberry (PEGylated MN). We also observed that their stability changed over 
time and measured their sizes and surface charges using laser scattering (0 day: 68.8 ± 5.1 nm and 0.7 
± 0.3 mV, 33 day: 69.2 ± 2.0 nm and −2.4 ± 0.7 mV, and 44 day: 63.2 ± 5.6 nm and −1.1 ± 0.9 mV, 
respectively). After PEGylated MN fabrication, we visually observed their colloidal stability for 15 
day. The day when the particles were produced was referred to as day 0. As shown in Figure 4b, 
these PEGylated MNs did not agglomerate for a long time (15 days) and remained very stable in the 
aqueous phase. Additionally, their sizes and charges barely changed over a 44-day period due to the 
PEGylation effect [23,26,28–30]. This finding signifies that the surface of the PEGylated MNs was 
well-coated with mPEG-PLA. Therefore, these particles could be stably presented in the water phase 
Figure 2. (a) The FTIR spectra of mPEG (5K) (black), lactide (red), and mPEG-PLA (blue) and (b) the
1H-NMR spectrum of mPEG-PLA (CDCl : Solvent).
ano aterials 2019, x, x FOR PEER REVIEW  5 of 12 
 
 
Figure 2. (a) The FTIR spectra of PEG (5K) (black), lactide (red), and PEG-PLA (blue) and (b) the 
1 - R spectru  of PE -PL  (C Cl3: Solvent). 
 
Figure 3. The determination of the critical micelle concentration (CMC) of mPEG-PLA using 
conductivity. 
3.2. Formulation and Characterization of PEGylated MNs  
We fabricated PEGylated magnetic nanoparticles composed of hydrophobic magnetic 
nanocrystals (MNCs) encapsulated by mPEG-PLA using the nano-emulsion method [3,7–13,16,20–
22,39,45,47,48]. The morphologies of these particles confirmed by TEM showed that MNCs were 
clustered spherically (Figure 4a). Based on this TEM image, we denoted this nanoparticle as a 
PEGylated magnetic nanoberry (PEGylated MN). We also observed that their stability changed over 
time and measured their sizes and surface charges using laser scattering (0 day: 68.8 ± 5.1 nm and 0.7 
± 0.3 mV, 33 day: 69.2 ± 2.0 nm and −2.4 ± 0.7 mV, and 44 day: 63.2 ± 5.6 nm and −1.1 ± 0.9 mV, 
respectively). After PEGylated MN fabrication, we visually observed their colloidal stability for 15 
day. The day when the particles were produced was referred to as day 0. As shown in Figure 4b, 
these PEGylated MNs did not agglomerate for a long time (15 days) and remained very stable in the 
aqueous phase. Additionally, their sizes and charges barely changed over a 44-day period due to the 
PEGylation effect [23,26,28–30]. This finding signifies that the surface of the PEGylated MNs was 
well-coated with mPEG-PLA. Therefore, these particles could be stably presented in the water phase 
3. The determination f the critical mi elle concentration (CMC) of mPEG-PLA using conductivity.
3.2. Formulation and Characterization of PEGylated MNs
We fabricated PEGyl ted mag etic nanoparticles composed of hydrophobic magnetic nanocrystals
(MNCs) encapsulated by mPEG-PLA using the nano-emulsion method [3,7–13,16,20–22,39,45,47,48].
The morphologies of these particles confirmed by TEM showed that MNCs were clustered spherically
(Figure 4a). Based on this TEM image, we denoted this nanoparticle as a PEGylated magnetic nanoberry
(PEGylated MN). We also observed that their stability changed over time and measured their sizes and
surface charges using laser scattering (0 day: 68.8 ± 5.1 nm and 0.7 ± 0.3 mV, 33 day: 69.2 ± 2.0 nm
and −2.4 ± 0.7 mV, and 44 day: 63.2 ± 5.6 nm and −1.1 ± 0.9 mV, respectively). After PEGylated MN
fabrication, we visually observed their colloidal stability for 15 day. The day when the particles were
produced was referred to as day 0. As shown in Figure 4b, these PEGylated MNs did not agglomerate
for a long time (15 days) and remained very stable in the aqueous phase. Additionally, their sizes and
charges barely changed over a 44-day period due to the PEGylation effect [23,26,28–30]. This finding
signifies that the surface of the PEGylated MNs was well-coated with mPEG-PLA. Therefore, these
particles could be stably presented in the water phase because of the hydrogen bonding with PEG
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molecules on the surface of PEGylated MNs and water molecules. As well, the poly dispersity index
(PDI) values were calculated based on the dynamic light scattering (DLS) analysis results. When each
value was substituted into the PDI equation (= Standard deviation2/particle size), the PDI values were
0.38, 0.06, and 0.49, respectively (Table 1 and Figure S1). The PDI values of the particles ranged from 0
to 0.0.8 in the nearly monodispersed and 0.08 to 0.7 in the uniformly dispersed [49]. Based on our PDI
values, we judged that PEGylated MN exhibited uniform dispersion and was acceptable to use in the
pharmaceutical filed.
Table 1. The size, poly dispersity index (PDI) values, and zeta potential data of PEGylated MN over
44 days.
Time Size (nm) PDI a Zeta (mV)
0 day 68.8 ± 5.1 0.38 0.7 ± 0.3
33 days 69.2 ± 2.0 0.06 −2.4 ± 0.7
44 days 63.2 ± 5.6 0.49 −1.1 ± 0.9
All data are depicted as the mean ± S.D, and N > 3, a PDI = (S.D.)2/Avg. size.
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3.3. Biocompatibility of the PEGylated MNs
Before applying the particles for in vivo imaging, first we evaluated the biocompatibility of the
PEGylated MNs against NIH3T6.7 cells using a MTT assay that was performed after incubation with
various concentrations overnight. The cell viability was maintained above 80% without inhibitory
effects on the cell proliferation within the PEGylated MN concentration range. Even when inorganic
MNCs were present in them, no effect on the cell viability was observed compared to that of mPEG-PLA
(Figure 7) [23,27,31–37,41,42].
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3.4. In Vivo MR Imaging
Next, we performed MR imaging in mouse xenograft tumor models using PEGylated MNs
to evaluate their diagnostic ability as MR imaging contrast agents. First, BALB/c-nude mice were
subcutaneously implanted in the proximal thigh with NIH3T6.7 cells for the xenograft mouse model,
and PEGylated MNs (200 µgFe+Mn in 200 µL buffer) were injected into the tail vein of the mouse
(intravenous injection). After a PEGylated MN injection, we observed that the tumor region became
gradually darker along the intra-tumoral blood vessels with a high MR signal intensity (Figure 8a).
In particular, the MR signal at the tumor region was consistently enhanced with darkening on the MR
image by increasing the ∆R2/R2Pre value by about 16.0% at 7 h postinjection relative to the preinjection
intensity (Figure 8c). Additionally, we clearly identified the MR signal changes by color-mapping the
tumor areas of the MR image. The color map image was intended to make the R2 value (MR signal)
change value visually clear. In a color map image, as the MR signal increases, the color changes from
blue to red. Therefore, in Figure 8b, the red color spread out gradually along the vascular distribution
as the MR signal increased, similar to the T2-weighted MR images. These results indicated that
PEGylated MNs were capable of sufficiently long-term circulation in the bloodstream (body) due to
their physical properties (e.g., PEGylation), thereby enabling the accumulation in tumor tissues by the
enhanced permeability and retention (EPR) effect.
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Figure 8. (a) The T2-weighted MR images of mice and (b) the color-map images of the polygonal region
with the white dashed line of Figure 8a. (c) The ∆R2/R2Pre (%) graph of the T2-weighted MR images
versus the time after an intravenous venous (I.V.) injection of PEGylated MNs (Pre: preinjection, IMM:
immediately following the injection, 1 h: 1 h following the injection, 3 h: 3 h following the injection,
and 7 h: 7 h following the injection). A 3.0 T human MR scanner was used.
4. Conclusions
In this study, we synthesized mPEG-PLA as an amphiphilic polymer using the ring-opening
polymerization method and then encapsulated the hydrophobic magnetic nanocrystals (MNCs) in an
organic solvent with mPEG-PLA using the nano-emulsion method to allow the stable dispersion in the
aqueous phase. At this time, the MNCs were uniformly assembled in raspberry form, and we named
it PEGylated magnetic nano-assemblies (PEGylated MNs). The PEGylated MNs exhibited a good
stability in an aqueous phase for an extended time due to the PEG molecules on the particle surface
(PEGylation effect) as well as an enough of an MR contrast effect due to the magnetic clustering effect
compared to those of a commercial MR contrast agent. In addition, we confirmed that PEGylated MNs
had a potential use as MRI agents for cancer detection through in vivo studies.
Supplementary Materials: The following are available online at http://www.mdpi.com/2079-4991/9/3/410/s1.
Figure S1: The size analysis graphs of PEGylated MNs over 44 days (a): 0 day, (b): 30 day and (c): 44 day.
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